Registry of Lobbyists

Registration - In-house Corporation

Janssen Inc. / Berkeley Vincent, President

Registration Information

In-house Corporation name: Janssen Inc.
Previous in-house corporation names
Responsible Officer Name: Berkeley Vincent, President 
Responsible Officer Change History
Initial registration start date: 2006-12-18
Registration status: Active
Registration Number: 953569-14483

Associated Communications

Total Number of Communication Reports: 224

Monthly communication reports in the last 6 months: 4

Version 2 of 39 (2007-08-23 to 2008-03-30)

Version 2 of 39 (2007-08-23 to 2008-03-30) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.

A. Information about Responsible Officer and Corporation

Corporation: Janssen Ortho Inc
19 Green Belt Drive
Toronto, ON  M3C 1L9
Canada
Telephone number: 416-449-9444
Fax number: 416-449-2658  
Responsible officer name and position during the period of this registration: Chris Halyk, General Manager  
Description of activities: Research based pharmaceutical company
 
The client is a subsidiary of the following parent companies: Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ
United States of America 08933

Coalition The corporation is not a member of a coalition.
Subsidiary: The corporation does not have any subsidiaries that could be affected by the outcome of the undertaking.
Other direct interests The corporation's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
 
Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? No
 

B. Lobbyists Employed by the Corporation

Name: Penny Albright
Position title: VP Government & Health Economics
Public offices held: No
 
Name: Lesia Babiak
Position title: Director, Federal Affairs & Health Policy
Public offices held: No
 
Name: Fiona Dunbar
Position title: VP Clinical Affairs
Public offices held: No
 
Name: Cathy Lau
Position title: VP Regulatory Affairs
Public offices held: No
 
Name: Veera Rastogi
Position title: VP Law
Public offices held: Yes
 

C. Lobbying Activity Information

Federal departments or organizations which have been or will be communicated with during the course of the undertaking: Canadian International Development Agency (CIDA), Finance Canada (FIN), Foreign Affairs and International Trade Canada (DFAITC), Health Canada (HC), Industry Canada, Members of the House of Commons, Patented Medicine Prices Review Board (PMPRB)
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Informal communications, Meetings, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format
 
Subject Matter: Areas of Concern: Health, Industry, Intellectual Property, International Trade, Science and Technology
 
Subject Matter: Retrospective: In two months preceding the date of filing, officers of Janssen-Ortho have been engaged in lobbying activities related to: a. The House of Commons Standing Committee on Health's (HESA) study of the Status of and progress accomplished under the Common Drug Review (CDR);b. The on-going work of the Patented Medicine Prices Review Board as it relates to the pricing of Janssen-Ortho molecules and drugs;c. Industry Canada's Regulations Amending the Patented Medicines (Notice of Compliance) Regulations ("PM(NOC) Regulations") and Health Canada's Regulations Amending the Food and Drug Regulations.
Subject Matter: Prospective: In the next six months, officers of Janssen-Ortho will be engaged in lobbying activities related to: a. The House of Commons Standing Committee on Health's (HESA) study of the Status of and progress accomplished under the Common Drug Review (CDR);b. The on-going work of the Patented Medicine Prices Review Board as it related to the pricing of Janssen-Ortho molecules and drug. c. Health Canada's proposal to add the drug tramadol to the Controlled Drugs and Substance Act (CDSA) and the Schedule of the Narcotic Control Regulations (NCR).
 

Details Regarding the Identified Subject Matter

Categories Description
Policy or Program Any future work of the Commission on the Future of Health Care in Canada.
Regulation Health Canada's proposal to add the drug tramadol to the Controlled Drugs and Substance Act (CDSA) and the Schedule of the Narcotic Control Regulations (NCR).
Regulation Health Canada's Regulations Amending the Food and Drug Regulations.
Policy or Program The House of Commons Standing Committee on Health's (HESA) study of the Status of and progress accomplished under the Common Drug Review (CDR).
Regulation The monitoring of Health Canada's enforcement of Canada's Food and Drugs Act and Regulations as they relate to the cross border sale of drugs to the United States.
Regulation The monitoring of Industry Canada's Regulations Amending the Patented Medicines (Notice of Compliance) Regulations ("PM(NOC) Regulations").
Policy or Program The on-going work of the Patented Medicine Prices Review Board as it relates to the pricing of Janssen-Ortho molecules and drugs.




Date Modified: